MedPointe – Board Of Directors

As Non-Executive Chairman of MedPointe, Tony Wild brings a wealth of experience gained in a global career of 30 years in the pharmaceutical industry. Until the merger of Warner-Lambert with Pfizer in June 2000, he served as Executive Vice President of Warner-Lambert and President of its Pharmaceutical Sector, with worldwide responsibility for Warner-Lambert’s pharmaceutical commercial operations and research and development. Under Tony’s leadership, Warner-Lambert’s pharmaceutical business grew from $2.1 billion in sales with 14,000 employees in 1995 to $7.8 billion in 1999 and an estimated $9.5 billion in 2000 with 21,000 employees. During this period, Tony oversaw the acquisition of Jouveinal (France) and Agouron (La Jolla) in 1999.

Dr. Wild was also a Founding Partner as well as President and CEO of MedPointe Capital Partners, LLC, a private equity capital partnership formed in 2000 whose goal was to create a leading company in the specialty pharmaceutical arena and which was achieved through the acquisition of Carter-Wallace Inc. and its transformation into MedPointe Pharmaceuticals. He was the company’s first Chairman and Chief Executive Officer until May 1, 2006, when he handed over the reins as CEO to MedPointe’s President, Paul R. Edick.

Prior to joining Warner-Lambert in 1995 (initially as President of Parke-Davis North America before assuming global responsibilities in 1996), Tony spent 22 years with the Schering-Plough Corporation in Japan, the Netherlands, South Africa, Sweden, Switzerland and the United States, culminating as President of Schering-Plough’s Japanese operations, a $500 million business, including a complex web of licensee/ licensor partnerships with major Japanese companies for almost 6 years. Prior to joining Schering-Plough, he was employed at Sandoz AG in Basel, Switzerland, as a Development Chemist, where he worked on optimization and simulation of chemical processes.

Dr. Wild serves on the Board of Directors of Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company which focuses on the therapeutic areas of oncology and inflammation. He is also a past Trustee of the Healthcare Institute of New Jersey, a past Chairman of the International Section of Pharmaceutical Research and Manufacturers of America, and a past Governor of the American Chamber of Commerce in Japan.

Dr. Wild graduated from the University of York with a B.A. honors degree in Chemistry and received a Ph.D. in Physical Chemistry from the University of Cambridge (Churchill College), both in the UK.

Paul R. Edick, President and Chief Executive Officer of MedPointe Pharmaceuticals, has assembled over the last twenty-eight years an outstanding track record of success in leading pharmaceutical organizations.

Mr. Edick joined MedPointe in 2002 as President of its Wallace Pharmaceuticals division. Shortly thereafter, he was named MedPointe President. Between 1994 and 2002, in a series of positions at G. D. Searle and its acquirer, Pharmacia Corporation, he led Searle’s US managed care organization (1994-95), its US marketing organization (1995-96), and its Global Pain & Inflammation Business – including the development of the launch strategy for Celebrex® (1996-97). In 1998, he assumed his first international leadership role, as he was named Searle’s VP-Canada & Latin America. A year later, he became President of Asia Pacific, Canada & Latin America. In 2000, upon Pharmacia’s acquisition of Searle, Mr. Edick was named Group Vice President and President, Asia Pacific/Latin America at Pharmacia.

His early career was focused on building basic skills in consumer products and prescription pharmaceuticals sales and marketing. He began his career as a Sales Representative at Procter & Gamble (1977-1978) and then joined Ortho Pharmaceutical, a division of Johnson & Johnson (1978-1990), where he became a US Regional Sales Manager in 1988. His first general management role was with Caremark, the former homecare services division of Baxter Healthcare (1990-1991). He further broadened his pharmaceutical marketing experience, domestically and internationally, with a Vice President, Group Account Management role at pharmaceutical ad agency, Hamilton Carver & Lee (1991-1994).

Mr. Edick serves on the Board of Directors of Informed Medical Communications, a leading communications company that delivers integrated biotechnology and pharmaceutical marketing programs for targeted and active groups of patients and medical professionals. He is also a Trustee of the Healthcare Institute of New Jersey,
Mr. Edick is a native of upstate New York and a graduate of Hamilton College.

Carlos A. Ferrer co-founded Ferrer Freeman & Company, LLC (FFC) in 1995 to provide private equity capital exclusively for companies in the health care industry. Based in Greenwich, CT, FFC manages two funds aggregating over $500MM of private equity capital. Limited partners include numerous corporate pension funds, state funds, university endowments, insurance companies and families with significant wealth. FFC also manages a partnership that co-invests with the main fund, for individuals involved in the health care industry, including CEOs, physicians and consultants. As of October 2003, FFC has invested and/or committed these funds to twenty-three portfolio companies in the provider, managed care, HCIT, device, workflow solutions and pharmaceutical sectors of the industry.

Prior to founding FFC, Mr. Ferrer was a managing director at Credit Suisse First Boston where he was employed for 17 years. From 1982 through 1995, he founded and served as head of its Health Care Investment Banking Group. In addition to MedPointe, he is a member of the board of directors of AMERIGROUP Corporation, Ardent Health Services, LLC, Concentra Managed Care, intelliClaim, Inc. and OrthoRx. He is also Vice Chairman of the board of the Cancer Research Institute.

Mr. Ferrer was born in Cuba, and holds a BA degree from Princeton University.

Ryan A. Harris is a Vice President working on U.S. venture and growth capital in the healthcare sector. He is based in New York.

Prior to joining Carlyle in 2002, Dr. Harris was a consultant in the West Coast Healthcare Practice of McKinsey & Co., working with a variety of biotechnology, pharmaceutical and medical device companies on corporate, R&D; and marketing strategy.

Dr. Harris holds an M.D. from the University of California, San Francisco, School of Medicine. He received an M.S. in health research and policy and B.A. in psychology from Stanford University, and attended Oxford University’s Magdalen College. He has authored over 25 scientific articles in peer-reviewed publications such as JAMA, Lancet, Annals of Internal Medicine, and the Journal of Health Economics.

Dr. Harris serves as a present or former member or observer on the Board of Directors for Align Technologies, AqueSys, ConnectiCare, MedPointe Pharmaceuticals, Qualicaps, Inc., Transport Pharmaceuticals, Proteus Biomedical and NeoVista.

Allan M. Holt is a Managing Director of The Carlyle Group, a global diversified private equity firm that manages approximately 13.5 billion of capital. Mr. Holt’s primary focus is on U.S. investment opportunities in the aerospace, defense and information technology industries. He is based in Washington, DC.

Mr. Holt joined Carlyle in 1991, initially with primary responsibilities as Senior Vice President and Chief Financial Officer of one of Carlyle’s portfolio companies, where he was involved in the negotiation and sale of the business. Prior to joining Carlyle, Mr. Holt spent three and a half years with Avenir Group, Inc., an investment and advisory group that acquired majority equity positions in small and medium-sized companies and provided active management support within its acquired companies. Mr. Holt was also previously with MCI Communications Corp., where as Director of Planning and Budgets, he managed a group responsible for the development, review and analysis of MCI’s multibillion dollar financial operating and capital plans. Before joining MCI, Mr. Holt was with Coopers & Lybrand.

Mr. Holt is a graduate of Rutgers University and earned his M.B.A. from the University of California, Berkeley.

Ernest J. Larini has more than 30 years of experience in the pharmaceutical industry, including 26 years at Warner-Lambert. He will chair the Board’s Audit Committee. Until the merger of Warner-Lambert with Pfizer in June 2000, Ernie served as Chief Financial Officer and Executive Vice President, Administration. Throughout his career at Warner-Lambert, he held various positions, including Vice President, Finance-Europe, Middle East and Africa Group; and Corporate Treasurer, Vice President and Controller. Ernie began his distinguished career at Merck & Co., Inc. as a Budget Analyst.

He serves on the Board of Directors for the New Jersey Symphony Orchestra, the Morris County (New Jersey) Chamber of Commerce, Saint Clare’s Hospital and the Tri-County Scholarship Fund. Ernie also is a member of The Conference Board’s Council of Chief Financial Officers.

Mr. Larini received his B.B.A. degree in Management from the University of Notre Dame and his M.B.A. degree in Finance from St. John’s University.

Richard U. De Schutter has a distinguished career in the pharmaceutical industry spanning numerous high-profile companies and leadership positions. He will chair the Board’s Organization and Compensation Committee. Most recently, he served as the Chairman and Chief Executive Officer of DuPont Pharmaceuticals Company, a worldwide business that focuses on research, development and delivery of pharmaceuticals to treat unmet medical needs against cancer, cardiovascular disease, CNS disorders, HIV and inflammatory disease. Formerly, Dick was a Director and Chief Administrative Officer of Pharmacia Corporation, which was created through the merger of Monsanto Company and Pharmacia & Upjohn in April 2000. At Monsanto, Dick was a Director, Vice Chairman and Chief Administrative Officer. From 1995 to 1999, he served as Chairman and Chief Executive Officer of G.D. Searle & Co., Monsanto’s wholly owned pharmaceutical subsidiary. His earlier appointments at Searle included President and Chief Operating Officer and President, International Operations.

Mr. DeSchutter serves on the Board of Directors of Atlanta-based ING Americas, Chicago-based General Binding Corporation, London-based Smith & Nephew plc, Palo Alto-based Varian, Inc., and is non-executive Chairman of the Board of Palo Alto-based Incyte Co.

Mr. De Schutter received his B.S. and M.S. degrees in Chemical Engineering from the University of Arizona and completed the Advanced Management Program at Columbia University. He is a recipient of the 1989 University of Arizona Centennial Medallion, awarded to highly distinguished alumni, as well as the university’s 1999 Technology & Management Lifetime Achievement Award.

Bahram Shirazi is a Managing Director with The Cypress Group, a private equity investment fund that currently manages more than $3.5 billion of equity capital on behalf of major pension funds, university endowments and other leading financial institutions. Bahram joined Cypress during its formation in April 1994. Previously, he worked at Lehman Brothers in the Merchant Banking Group, which he joined in 1989.

Mr. Shirazi received a BSEE degree from Tufts University and an M.B.A. degree from Columbia University.

James A. Stern is Chairman, The Cypress Group. Jim Stern headed Lehman Brothers merchant banking group before leaving that firm to help found The Cypress Group. During his 20-year tenure with Lehman, he held senior management positions where he was responsible for the high yield and primary capital markets groups. He also served as co-head of investment banking and was a member of Lehman’s operating committee. Mr. Stern has broad industrial experience and particular knowledge of the retailing and consumer products industries. Before graduating from Harvard Business School, Mr. Stern received a BS degree from Tufts University where he is a trustee. He is currently a director of Lear Corporation, AMTROL, WESCO International, Affinia Group INC. and MedPointe Inc.